Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina

Core Insights - Hemostemix Inc. is set to present clinical data on its VesCell™ (ACP-01) therapy for treating Severe Angina Pectoris, highlighting its efficacy compared to current standard care options [1][2]. Clinical Study Findings - The clinical trial demonstrated significant improvements in exercise tolerance, with the six-minute walk distance increasing from 333.65 meters at baseline to 414.95 meters at 3 months and 413.25 meters at 6 months (P<0.001) [4]. - Exercise capacity, measured in Metabolic Equivalents (METs), rose from 5.62 at baseline to 6.73 at 3 months and 7.09 at 6 months (P<0.004) [4]. - Ischemia, indicated by SPECT-MIBI perfusion defects, decreased from 38.46% at baseline to 23.89% at 3 months and 21.05% at 6 months (P<0.004) [4]. - The Canadian Cardiovascular Society (CCS) angina score improved from 2.1 at baseline to 1.05 at 3 months and 1.18 at 6 months (P<0.001), indicating a reduction in chest pain severity [4][5]. Management Perspective - The CEO of Hemostemix emphasized the unique approach of using autologous stem cells to treat ischemia, highlighting the therapy's safety and significant clinical relevance [7]. - The company plans to leverage revenue from the treatment in Florida to fund a double-blind randomized clinical trial for global approval of ACP-01 [7]. Company Background - Hemostemix is an established autologous stem cell therapy company, recognized for its innovative VesCell™ (ACP-01) treatment, which has shown promise in various cardiovascular conditions [9]. - The company has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed journals, underscoring its commitment to research and development in the field [9].